"Russian health authorities have taken precautionary measures in response to the death of a woman who worked at an anti-plague research facility," reports Axios, "but have not confirmed that she contracted plague." On Sept. 25, 28-year-old Daria Shipilova, who worked at an anti-plague research institute in Russia's Irkutsk region, broke a test tube containing the pneumonic plague pathogen, local reports said. Shipilova was admitted to a hospital on Sept. 29 with symptoms of severe pneumonia and died overnight between Oct. 1 and Oct. 2. After her death, authorities imposed quarantines at several medical facilities in the region and placed nearly 200 people who had come into contact with Shipilova under medical observation. Irkutsk Gov. Igor Kobzev said those being monitored showed no signs of illness and had tested negative... Russia's public health agency said Shipilova had "pneumonia of unknown etiology" and that further testing found no microorganisms linked to her work. The agency said the epidemiological situation in the region remains stable. Plague is a potentially life-threatening bacterial disease but can be cured with antibiotics when treated promptly, according to the Centers for Disease Control and Prevention. CNN reports that according to Russian state media agency TASS, it remains unclear exactly what was released: The head of the neighboring republic of Buryatia, Alexei Tsydenov, said earlier that the employee — a 28-year old woman — died "possibly from the plague." He also noted that "there are no plague outbreaks" in Buryatia. The governor of Irkutsk, Igor Kobzev, urged calm on Friday, saying that an extraordinary meeting of the regional anti-epidemic commission was held with Russia's chief state doctor. The meeting was in connection with a "suspected case of a particularly dangerous infection affecting a resident of the region," Kobzev said on Telegram.... The infection in the Irkutsk region is "most likely not the plague, but even if confirmed, there will be no spread of this disease," a previous head of Rospotrebnadzor, Gennady Onishchenko, said on Friday. Onishchenko told the state news agency TASS that the onset of cold weather would likely prevent transmission. Thanks to long-time Slashdot reader schwit1 for sharing the news.

Read more of this story at Slashdot.

An anonymous reader quotes a report from The Guardian: It is the bane of every fruit bowl: sliced banana that turns brown before it has reached the table. But such woes could soon be a thing of the past, with gene-edited bananas that keep their freshly peeled color now one step closer to reaching British shoppers. According to Tropic, the Norwich-based agricultural-biotechnology company that developed the fruit, the bananas have the same taste and texture but stay "fresh, yellow and appetizing long after peeling and slicing." Gilad Gershon, the chief executive of Tropic, said the flesh of the new banana resisted browning for an extra day or two -- and longer if chilled. He added that the innovation could make it easier to add bananas to prepackaged products such as fruit salads and breakfast pots, as well as reducing waste. [...] Tropic developed the bananas by using a gene-editing technology called Crispr-Cas9 to alter all three copies of a single gene within the fruit. As a result, they were able to reduce the production of polyphenol oxidase, an enzyme that causes browning. A similar approach has been effective in reducing browning in other produce, including mushrooms. Tropic said the non-browning bananas could reduce food waste and CO2-equivalent emissions along the supply chain by more than 25%. "This could support an annual reduction in CO2 emissions of over 9m tonnes in the banana export market alone," the company said. [...] Gershon said Tropic had gained regulatory approval for the non-browning bananas in 10 other countries including Japan, Brazil and the Philippines. The fruit is already being grown in Latin America.

Read more of this story at Slashdot.

"New research led by Stanford Medicine reveals that what we call the brain is two distinct organs that evolved independently over hundreds of millions of years," Stanford Medicine announced this week: The new research finding shows that the human brain consists of two ancient nervous systems cleverly packaged together — a more primitive part that regulates our hearts' beating, our breathing and other functions, and another that makes us distinctly human, capable of poetry, mathematics and wondering about our own origins. The discovery could help explain why scientists have struggled for decades to grow certain types of brain cells in the laboratory — and it opens new avenues for studying devastating diseases that affect the brain stem... [S]cientists have struggled for decades to generate human hindbrain neurons in the laboratory. This gap has hampered research into devastating diseases affecting the brain stem, including spinal muscular atrophy and amyotrophic lateral sclerosis... The researchers' breakthrough came from studying the earliest moments of embryonic development... [Study co-authors Carolyn Dundes and Rayyan Jokhai] discovered that the hindbrain follows a separate developmental path, running in parallel to — rather than branching off from — the pathway that creates the forebrain and midbrain... This revelation explained decades of frustration in the field — scientists had been trying to turn one type of progenitor cell into another that it is fundamentally incapable of becoming... Armed with this knowledge, the researchers for the first time successfully coaxed human pluripotent stem cells (a kind of cell that can create any cell in the human body) to become functional hindbrain motor neurons in the laboratory... Finally, the researchers looked back over 550 million years of evolutionary time. They found the same two-origin brain pattern in chickens; zebrafish; and, remarkably, in acorn worms, tiny creatures living on the ocean floor that share a distant common ancestor with humans. Jellyfish, which diverged from humans about 600 to 700 million years ago, have two nervous systems at different ends of their body. "Our research suggests that evolution took two existing neural systems and pushed them together spatially," Loh said. "Having the brain as one organ would probably be more efficient, but we rely on this primordial way to make the brain as two separate pieces." Thanks to Slashdot reader Beeftopia for sharing the article.

Read more of this story at Slashdot.

"Billionaire Bill Ackman's life was upended this February when his 26-year-old daughter collapsed in her Brooklyn apartment, suffering a brain hemorrhage that would render her unable to move, speak or see," writes the Washingon Post. But then... The hedge fund manager did what any good father would do — at least, any father with vast financial resources and what friends describe as a "Mr. Fix-It" tendency. He sprung into action, getting her topline care at New York City's Mt. Sinai Hospital and consulting a network of well-connected friends all over the world. He helped her access a novel cell therapy that has been gaining traction among longevity enthusiasts, who are seeking ways to prolong human life. And then — motivated by a newfound desire to accelerate scientific research — he vowed to spend more than $400 million to launch an institute dedicated to longevity and brain health... He posted this week that the U.S. Food and Drug Administration, in May, gave his daughter Lucy's medical team a first-time emergency authorization to transplant mitochondria — the energy-producing part of human cells — from her leg muscle to her eyes, in the hopes that the tiny cell powerhouses would facilitate healing in her optic nerves and perhaps even restore her vision. Ackman's story highlights the increasingly prominent role of the ultra-wealthy in making expensive medical bets on longevity treatments and other novel therapies, altering the direction of research as federal funding for science declines in the second Trump administration. But his saga is a deeply personal one, spurred by his daughter's medical crisis. The focus on longevity by Ackman, who made billions on Wall Street as a hedge fund manager, is aligned with similarly ambitious efforts from some of Silicon Valley's biggest names. OpenAI CEO Sam Altman has backed Retro Biosciences, a start-up whose goal is to add 10 healthy years to the human lifespan through cellular reprogramming. Amazon founder Jeff Bezos is reportedly a funder of Altos Labs, which focuses on cellular rejuvenation and resilience... Billionaire investor Peter Thiel, Google co-founder Sergey Brin and Oracle co-founder Larry Ellison are also deeply invested in life-extension methods and attempts to rewrite the biology of aging... The therapy given to Ackman's daughter Lucy, known as mitochondrial transplantation, is of great interest not only to people who have suffered injuries, but to longevity-focused scientists who believe that mitochondria may hold promise for reversing some of the effects of aging... In recent years, scientists have discovered that mitochondria have many other functions beyond converting food into energy. They serve as clearinghouses for damaged cells, opening up the possibility that they can help with cell regeneration and healing, said Daria Mochly-Rosen, professor of chemical and systems biology at the Stanford University School of Medicine and co-author of " The Life Machines: How Taking Care of Your Mitochondria Can Transform Your Health." "I am one of those who believes that focusing on mitochondrial health is a way to address many human diseases, including aging itself," she said. "It's exciting."

Read more of this story at Slashdot.

The FDA has cleared the first Alzheimer's blood test for symptomatic patients as young as 40. The test measures amyloid and tau biomarkers from a single blood draw and identified positive biomarkers with 97.6% accuracy in a validation study. New Atlas reports: PrecivityAD2 is a single blood test that quickly assesses the proteins amyloid and tau, using mass spectrometry to measure plasma AB42/40 and p-tau217/np-tau217. The results are then scored, qualifying as negative, likely positive, or positive for AD. "Just over a year ago, there were no FDA-cleared blood tests for Alzheimer's, and now we have three," Isobel Coleman, chief executive officer of the Alzheimer's Drug Discovery Foundation (ADDF), said in a statement. "This is a proof point that sustained, early investment in translational science plays a catalytic role in moving promising ideas from the lab to patients." In a recent clinical validation study, 1,142 symptomatic adults were tested using PrecivityAD2. The process accurately identified 97.6% of positive biomarkers. What's more, the results remained consistent even in patients with comorbidities like chronic kidney disease and diabetes, which can distort plasma amyloid samples. It's worth noting that the test isn't intended for general health screenings, but for patients who already show some cognitive decline. "As PrecivityAD2 and tools like it move further into clinical practice, they will enable earlier detection, sharpen clinical trials, and build the foundation for precision medicine and combination therapies," Coleman added.

Read more of this story at Slashdot.

Reuters reports "a major success in a new field of cancer treatment this week, as Moderna and Merck announced a personalized mRNA cancer vaccine "reduced the risk of recurrence and spread of melanoma in a late-stage trial". The vaccine was tested with Merck's widely used immunotherapy drug Keytruda: Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview. This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells, and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone... Interim results of the ongoing study, released on Wednesday, found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of preventing tumors from spreading to other parts of the body, compared with Keytruda alone. When the vaccine is injected into a patient, the patient's cells produce copies of mutations for the immune system to recognize and destroy... Merck said the companies are already in talks with regulators about the treatment. "Merck, Moderna and other companies are testing similar approaches against lung, breast and pancreatic cancers," the article points out. It adds that Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, "said the Moderna results could signal a new era for treating solid-tumor cancers." More from CNN: The trial result is "a monumental leap forward," validating mRNA technology as a cancer treatment, said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology... Roche and BioNTech, whose mRNA technology was used in the Pfizer COVID vaccines, are testing a similar treatment called autogene cevumeran in mid-stage studies in colon and pancreatic cancer patients who have undergone surgery. Results of the colon cancer trial are expected in 2027, with pancreatic trial results to follow in 2031. "We should be hearing results from multiple studies over the next few years and there's every reason to hope now, with this news, that many of them will be positive," said Dr. Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center and president-elect of the American Association for Cancer Research.

Read more of this story at Slashdot.